Press Releases Tarsus Pharmaceuticals, Inc.

Equities

TARS

US87650L1035

Market Closed - Nasdaq Other stock markets 04:00:03 2024-05-31 pm EDT			5-day change	1st Jan Change
33.03 ^USD	-4.92%		-5.66%	+63.11%

May. 31	Certain Restricted Stock Units of Tarsus Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024.	CI
May. 31	Certain Options of Tarsus Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tarsus to Participate in Upcoming Investor Conferences	May. 29	GL
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference	May. 09	GL
Tarsus Pharmaceuticals : Corporate Presentation	May. 08	PU
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements	May. 08	GL
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024	May. 01	GL
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon	Apr. 23	AQ
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon	Apr. 23	GL
Tarsus Pharmaceuticals : Corporate Presentation	Mar. 19	PU
Tarsus to Participate at Upcoming Investor Conferences	Mar. 05	GL
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis	Mar. 05	GL
Tarsus Announces Pricing of $100.0 Million Public Offering	Mar. 01	GL
Tarsus Announces Proposed $100.0 Million Public Offering	Feb. 29	GL
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements	Feb. 27	GL
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease	Feb. 22	GL
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease	Feb. 22	AQ
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024	Feb. 20	GL
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024	Feb. 20	AQ
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference	Jan. 31	GL
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference	Jan. 31	AQ
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites	Dec. 11	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Tarsus Pharmaceuticals, Inc.

Equities

TARS

US87650L1035

Press Releases

Filters